These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 9314567)

  • 1. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors.
    Ashley DM; Faiola B; Nair S; Hale LP; Bigner DD; Gilboa E
    J Exp Med; 1997 Oct; 186(7):1177-82. PubMed ID: 9314567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pulsing of dendritic cells with cell lysates from either B16 melanoma or MCA-106 fibrosarcoma yields equally effective vaccines against B16 tumors in mice.
    DeMatos P; Abdel-Wahab Z; Vervaert C; Hester D; Seigler H
    J Surg Oncol; 1998 Jun; 68(2):79-91. PubMed ID: 9624036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor cell lysate-pulsed dendritic cells induce a T cell response against colon cancer in vitro and in vivo.
    Wu YG; Wu GZ; Wang L; Zhang YY; Li Z; Li DC
    Med Oncol; 2010 Sep; 27(3):736-42. PubMed ID: 19669608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced therapeutic efficacy of tumor RNA-pulsed dendritic cells after genetic modification with lymphotactin.
    Zhang W; He L; Yuan Z; Xie Z; Wang J; Hamada H; Cao X
    Hum Gene Ther; 1999 May; 10(7):1151-61. PubMed ID: 10340547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
    Wang J; Saffold S; Cao X; Krauss J; Chen W
    J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells.
    Cao X; Zhang W; Wang J; Zhang M; Huang X; Hamada H; Chen W
    Immunology; 1999 Aug; 97(4):616-25. PubMed ID: 10457215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapeutic potential of tumor antigen-pulsed and unpulsed dendritic cells generated from murine bone marrow.
    Yang S; Darrow TL; Vervaert CE; Seigler HF
    Cell Immunol; 1997 Jul; 179(1):84-95. PubMed ID: 9259775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma.
    Bellone M; Cantarella D; Castiglioni P; Crosti MC; Ronchetti A; Moro M; Garancini MP; Casorati G; Dellabona P
    J Immunol; 2000 Sep; 165(5):2651-6. PubMed ID: 10946294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the immunoregulator SRA/CD204 potentiates specific dendritic cell vaccine-induced T-cell response and antitumor immunity.
    Yi H; Guo C; Yu X; Gao P; Qian J; Zuo D; Manjili MH; Fisher PB; Subjeck JR; Wang XY
    Cancer Res; 2011 Nov; 71(21):6611-20. PubMed ID: 21914786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen.
    Xia D; Zheng S; Zhang W; He L; Wang Q; Pan J; Zhang L; Wang J; Cao X
    J Mol Med (Berl); 2003 Sep; 81(9):585-96. PubMed ID: 12937899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of anti-tumor immunity by vaccination with dendritic cells pulsed with anti-CD44 IgG opsonized tumor cells.
    Pilon-Thomas S; Verhaegen M; Kuhn L; Riker A; Mulé JJ
    Cancer Immunol Immunother; 2006 Oct; 55(10):1238-46. PubMed ID: 16315029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant adenovirus-transduced dendritic cell immunization in a murine model of central nervous system tumor.
    Broder H; Anderson A; Odesa SK; Kremen TJ; Liau LM
    Neurosurg Focus; 2000 Dec; 9(6):e6. PubMed ID: 16817689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts.
    Nair SK; Snyder D; Rouse BT; Gilboa E
    Int J Cancer; 1997 Mar; 70(6):706-15. PubMed ID: 9096653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells.
    Yasuda T; Kamigaki T; Nakamura T; Imanishi T; Hayashi S; Kawasaki K; Takase S; Ajiki T; Kuroda Y
    Oncol Rep; 2006 Dec; 16(6):1317-24. PubMed ID: 17089056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dendritic cells pulsed with placental gp96 promote tumor-reactive immune responses.
    Zheng H; Liu L; Zhang H; Kan F; Wang S; Li Y; Tian H; Meng S
    PLoS One; 2019; 14(1):e0211490. PubMed ID: 30703157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Type I-polarized BRAF-pulsed dendritic cells induce antigen-specific CD8+ T cells that impact BRAF-mutant murine melanoma.
    Cintolo JA; Datta J; Xu S; Gupta M; Somasundaram R; Czerniecki BJ
    Melanoma Res; 2016 Feb; 26(1):1-11. PubMed ID: 26451873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effective immunotherapy against murine gliomas using type 1 polarizing dendritic cells--significant roles of CXCL10.
    Fujita M; Zhu X; Ueda R; Sasaki K; Kohanbash G; Kastenhuber ER; McDonald HA; Gibson GA; Watkins SC; Muthuswamy R; Kalinski P; Okada H
    Cancer Res; 2009 Feb; 69(4):1587-95. PubMed ID: 19190335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potentiation of immunologic responsiveness to dendritic cell-based tumor vaccines by recombinant interleukin-2.
    Shimizu K; Fields RC; Redman BG; Giedlin M; Mulé JJ
    Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S67-75. PubMed ID: 10685663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Ad hTRP2 - mediated immunity against melanoma is enhanced by dendritic cells pulsed with peptide].
    Tan XH; Liu C; Wan YH
    Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):658-61. PubMed ID: 17274369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Central nervous system tumor immunity generated by a recombinant listeria monocytogenes vaccine targeting tyrosinase related protein-2 and real-time imaging of intracranial tumor burden.
    Prins RM; Bruhn KW; Craft N; Lin JW; Kim CH; Odesa SK; Miller JF; Liau LM
    Neurosurgery; 2006 Jan; 58(1):169-78; discussion 169-78. PubMed ID: 16385341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.